Personalizing Precision Medicine

Kristin Pothier will be exploring success stories in precision medicine deals at the 2019 BIO International Convention. Learn more.

Personalizing Precision Medicine: A Global Voyage from Vision to Reality dives into the dynamic world of precision medicine and how it has evolved under the influence of the researchers, physicians, companies, payers and patients who are translating vision to reality. Each aspect of this burgeoning field is illustrated in the context of scientific, clinical, commercial and cultural milestones worldwide.

This is an important read if you are a business leader interested in how to navigate the precision medicine space, a friend supporting a loved one with a cancer diagnosis, an educator trying to explain medical complexity today, or someone curious about how the explosion of personalized data and the convergence of historically separate stakeholders has transformed the global health care landscape for the healthy and the ill. Here, both the science and the human impact of precision medicine are united in a single, approachable volume.

Based on EY-Parthenon Global Head of Life Sciences Kristin Pothier’s decades of experience in precision medicine, her research into the evolution of the field and more than 100 interviews with industry leaders, physician thought leaders and patients and their caregivers, Personalizing Precision Medicine highlights the triumphs and challenges of precision medicine on a global scale.

Personalizing Precision Medicine is available at all major online booksellers and Order your copy today.

Download the Personalizing Precision Medicine brochure.

Economic and clinical impact of precision medicine

Precision medicine is a targeted approach to patient care, designed to deliver the right treatment to the right patient at the right time, resulting in better clinical outcomes and more efficient and affordable care. Precision medicine positively impacts the cost of care by eliminating unsuccessful treatment modalities, delivering the right treatment the first time and reducing drug development costs through more targeted patient impact studies. The principles of precision medicine apply to all populations, sick and well; and patients worldwide are benefiting from its approach.

Liz Lord owns Arlva Homes, LLC, a residential real estate company in Northern Virginia. Previously, Liz practiced commercial real estate law in the private sector and also worked at the U.S. Department of State on environmental matters both overseas and domestically. Liz is a breast cancer slayer who successfully used cold caps during her chemotherapy to prevent hair loss. Inspired by that experience, she is founder of Cold Capital Fund, a non-profit corporation aiming to provide funds to under-resourced chemotherapy patients in the Washington DC area trying to prevent hair loss. Liz lives in Arlington, Virginia with her husband and two young children.

Global access to advances in precision medicine

Precision medicine is a gateway to efficient, affordable health care for everyone, but there are regions of the world that simply lack access and infrastructure to support the targeted approaches we are celebrating. Increasing access to targeted treatment and precision modalities within these regions is a priority for global non-governmental organizations, nonprofit organizations and public/private partnerships.

Patricia J. Goldsmith joined CancerCare in 2014 as Chief Executive Officer, overseeing the vision and direction of the organization. Trish has more than 20 years of nonprofit management and strategic planning experience, and has a proven track record of success in hospital and physician academic organizations, as well as nongovernmental health care organizations. She previously served as Executive Vice President and Chief Operating Officer at the National Comprehensive Cancer Network (NCCN). Prior to joining NCCN, Trish was Vice President for Institutional Development, Public Affairs and Marketing at the H. Lee Moffitt Cancer Center & Research Institute. Trish has studied at the Pennsylvania State University, the University of Missouri Bloch School of Business and the Harvard School of Public Health.

The future of precision medicine: Increased investment and new technologies

Modern technologies continue to evolve to allow people to personally improve their health and provide researchers with new tools to advance precision medicine worldwide. Thanks to technological advances in sequencing technology, it is now possible to sequence a human’s entire genome for less than $1,000.

Artificial intelligence, which involves using computers to perform tasks that normally require human intelligence, helps researchers make sense of health and lifestyle-related data and is starting to help physicians and patients decide which treatment will be most effective. Investors are equally excited about these emerging technologies, as evidenced by the investment of more than $600 million of venture funding alone within consumer diagnostics and precision medicine since 2014.

Soon, groundbreaking science could enable us to treat cancer with a patient’s own cells or remove damaged genes from embryos — with untold impact on reducing human disease. We must prioritize ongoing research, investment and collaboration in precision medicine, as the results can revolutionize the medical industry — saving and extending millions of lives on a worldwide scale.

“A tour de force — Kristin brings precision medicine into focus with clear and practical commentary. Personalizing Precision Medicine is exactly what [the] health care establishment needs now — how to make it real and cost effective.” – Mara Aspinall, President and CEO, Health Catalysts, Co-Founder, Arizona State University School of Biomedical Diagnostics

“As a surgeon, I find the importance of precision surgery to be obvious, but describing precision medicine has been a challenge — until now! Kristin explains it all, from the basic science to compelling, personal stories that make the science come to life. It helps us examine precision medicine from all angles and helps us as physicians explain it comprehensively to others.” – Tenley Albright, Director of the MIT Collaborative Initiatives, former surgeon, and World and Olympic Champion figure skater

“As a young patient with breast cancer, it was overwhelming to research every aspect of my care to make sure it was personalized for me. This book, Personalizing Precision Medicine, should be one of the very first tools to educate people like me, and those professionals who supported me. The facts, mixed with personal stories from all around the world, were something I wish I’d had when I was first diagnosed.” – Liz Lord, Breast cancer slayer, former US diplomat and owner of ArlVa Homes LLC


Kristin has spoken at the following events:

The Business of Medicine LinkedIn blog series

To further highlight the triumphs and challenges of precision medicine on a global scale, Kristin and the EY-Parthenon Life Sciences team explore more topics through a LinkedIn blog series, The Business of Medicine.

Life Sciences Global Tour: Featured regional summaries

Despite obstacles, regions around the world are seeking innovative therapies, diagnostics, devices and services in ways that are customized to their populations. The Life Science team explores through a series of regional summaries.

About our Life sciences practice

Visit our Life sciences page to learn more about the EY-Parthenon Life sciences practice, including:

  • Our capabilities
  • Our perspectives
  • Our events
  • Our people